跳至主要内容
临床试验/JPRN-UMIN000006946
JPRN-UMIN000006946已完成未知

Efficacy and safety of neoadjuvant CEX-XT treatment for triple-negative breast cancer - NeoXX trial

Department of breast and endocrine surgery, Hyogo college of medicine0 个研究点目标入组 40 人开始时间: 2012年1月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 70years-old(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1. Another cancer diagnosed within 5 years 2. Pregnant or nursing women 3. Male patients 4. With history of serious drug allergy 5. With interstitial pneumonitis or lung fibrosis 6. Infection or possible infection associated with clinical symptoms such as fever 7. With symptom of varicella 8. With uncontrollable pleural effusion, or pericardial effusion 9. With severe edema 10. With severe peripheral neuropathy 11. Usual treatment with steroid 12. With severe psychological complication 13. Bilateral breast cancer 14. Cases who physician judged improper to entry this trial

研究者

发起方
Department of breast and endocrine surgery, Hyogo college of medicine

相似试验